Tag - VYNT

H.C. Wainwright initiated coverage of Vyant Bio (NASDAQ:VYNT) with a “buy” rating and price target of $5. The stock closed at $2.21 on Oct. 5. Vyant is a biotechnology company focused on identifying therapeutic drugs...